Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2025-04-25 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
拓新药业集团股份有限公司2024年度募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds" for the year 2024. It contains detailed information about the amount of funds raised, their storage, usage, management, and compliance with regulatory requirements. The report includes auditor's verification and opinions, detailed tables of fund usage, changes in project implementation, and compliance with Shenzhen Stock Exchange regulations. The document is lengthy (15,000 characters) and contains substantive financial and operational data related to the use of capital raised by the company. This type of report is a specialized audit or verification report focusing on the use of raised capital, not a full annual report or earnings release. It is not a simple announcement or certification but a detailed audit-related report. Therefore, it fits best under the category Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
2024年年度财务报告
Audit Report / Information Classification · 95% confidence The document is titled as a financial report of 拓新药业集团股份有限公司 and contains a detailed audit report section with audit opinions, audit basis, and key audit matters. It includes comprehensive financial statements such as consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the fiscal year ending December 31, 2024. The presence of an audit opinion with a standard unqualified opinion, detailed financial data, and notes indicates this is a standalone audit report rather than a full annual report or an announcement. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just a certification or announcement. Therefore, the document fits the category of an Audit Report / Information (AR). FY 2024
2025-04-25 Chinese
关于拓新药业集团股份有限公司2024年度营业收入扣除情况的专项说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项说明" (special explanation) regarding the 2024年度营业收入扣除情况 (2024 annual operating revenue deduction situation) of 拓新药业集团股份有限公司. It includes a detailed table of revenue deductions and references an audit report issued by a registered accounting firm. The document states it is prepared according to regulatory guidelines and is intended to be read alongside the audited financial statements for the 2024 fiscal year. The content is focused on explaining specific revenue deductions rather than presenting a full annual report or interim report. The document length is 2143 characters, which is relatively short and more of a supplementary explanation rather than a full financial report. It is not a simple announcement of a report publication but a detailed explanation with audit confirmation. This fits best with the category of Audit Report / Information (AR), which includes standalone audit reports and related accounting information excluding full annual reports. Therefore, the classification is AR with high confidence. FY 2024
2025-04-25 Chinese
北京市康达律师事务所关于拓新药业集团股份有限公司2022年限制性股票激励计划第三个归属期归属条件未成就及作废部分限制性股票事项的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of certain restricted stock awards under a 2022 restricted stock incentive plan of a company. It references specific board and shareholder approvals, legal compliance with Chinese securities laws and stock exchange rules, and audit reports confirming performance targets were not met, leading to the cancellation of unvested restricted shares. The document is a standalone legal opinion on a specific corporate action related to stock incentives, not a full financial report, earnings release, or general regulatory filing. It is not an announcement of a report publication but a substantive legal opinion document. Therefore, it fits best under the category of Regulatory Filings (RNS) as it is a legal compliance document related to corporate governance and securities regulation, but does not fit the more specific categories like MANG or DEF 14A which relate to management changes or remuneration disclosures respectively.
2025-04-25 Chinese
拓新药业集团股份有限公司2024年度非经营性资金占用及其他关联资金往来的专项说明
Audit Report / Information Classification · 90% confidence The document is titled as a "2024年度非经营性资金占用及其他关联资金往来的专项说明" which translates to a "Special Explanation on Non-operating Fund Occupation and Other Related Party Fund Transactions for 2024." It includes a summary table of related party transactions and non-operating fund occupation for the year 2024. The document references an audit report issued on April 25, 2025, with an unqualified opinion on the 2024 financial statements. The document is prepared according to regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange disclosure rules. It is a detailed explanatory note on specific financial matters related to related party transactions and non-operating fund occupation, which is a type of audit-related disclosure but not the full audit report itself. The document length is 3027 characters, which is relatively short and focused on a specific audit-related topic rather than a full annual report or audit report. Given the nature of the document as a special explanation related to audit findings and regulatory requirements, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related disclosures excluding full annual reports. FY 2024
2025-04-25 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司首次公开发行股票并在创业板上市之持续督导保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" which translates to a "Continuous Supervision Sponsorship Summary Report" related to the initial public offering (IPO) and listing of a company on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It details the sponsor's ongoing supervision work post-IPO, including compliance with regulatory requirements, changes in project implementation, use of raised funds, and financial performance updates. The document includes detailed descriptions of the sponsor's duties, changes in sponsorship representatives, and specific financial and operational updates related to the IPO proceeds and company performance. It is not a full annual or quarterly financial report, nor is it an earnings release or a simple announcement. It is a comprehensive report on the sponsor's continuous supervision and due diligence following the IPO, which aligns with the category of "Capital/Financing Update" (CAP) because it focuses on the IPO process, fundraising, and ongoing capital use and supervision. The document length (7737 characters) and detailed content confirm it is a substantive report rather than a brief announcement or certification. Therefore, the best fitting classification is CAP with high confidence.
2025-04-25 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.